Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

That kind of shot was first used during the Covid-19 pandemic, but the health secretary has been sharply critical of the ...

Pfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt ...

In a report released today, Mani Foroohar from Leerink Partners maintained a Sell rating on Moderna, with a price target of $18.00. The company’s shares opened today at $28.20. Take advantage of ...

US Health and Human Services is “winding down” its mRNA vaccine development and will instead fund other vaccine platforms through the Biomedical Advanced Research and Development Authority, the agency ...

The Department of Health and Human Services will cancel contracts and pull funding for some vaccines that are being developed ...

In addition to Oppenheimer, Moderna also received a Hold from Citi’s Geoff Meacham in a report issued today. However, on the same day, Bank of America Securities reiterated a Sell rating on Moderna ...

HHS Secretary Robert F. Kennedy Jr. says the federal government is calling off around $500 million worth of vaccine ...

HHS announced that it will no longer fund internal department research for mRNA vaccines for upper respiratory viruses like flu and COVID-19.

Health and Human Services Secretary Robert F. Kennedy Jr. has canceled $500 million in vaccine development after “listening ...

The company posted strong second-quarter results and reaffirmed its guidance for 2025. Enbridge posted EBITDA of C$4.6 ...